Figure 7.

Inhibition of JAK1/2 does not prevent fibrosis or preserve lymphatic function and fibrosis independently inhibits lymphatic function. A) Representative photographs of JAK1/2 inhibitor or control-treated mouse tails 6 wk postoperatively. B, C) Change in tail volume (B) and subcutaneous tissue thickness (C) in JAK1/2 inhibitor or control treated mice 6 wk postoperatively. D) Peak nodal uptake of ^99mTc in JAK1/2 inhibitor or control-treated animals 6 wk postoperatively. E) Subcutaneous tissue thickness of animals treated with bleomycin or PBS. F, G) Peak nodal uptake of ^99mTc by sacral lymph nodes (F) and microlymphangiography/proximal fluorescence (G) in animals treated with bleomycin, bleomycin and IL-4mAb, or PBS control. H) Quantification of lectin⁺ capillary lymphatics as a percentage of total lymphatics (left panel) and representative whole mount lectin stain (right panel) in bleomycin/IL-4mAb and bleomycin/control antibody-treated animals. White arrows indicate capillary lymphatics; dotted circles represent pooled areas of lectin in interstitial space.